Targeted delivery to neuroblastoma of novel siRNA-anti-GD2-liposomes prepared by dual asymmetric centrifugation and sterol-based post-insertion method

Pharm Res. 2011 Sep;28(9):2261-72. doi: 10.1007/s11095-011-0457-y. Epub 2011 May 19.

Abstract

Purpose: To optimise and simplify preparation of targeted liposomes for efficient siRNA delivery to neuroblastoma, the most common solid tumour in early childhood.

Methods: Liposomes containing siRNA were prepared by combining the novel dual asymmetric centrifugation (DAC) method and the recently optimised sterol-based post-insertion technique (SPIT) to couple anti-GD2 antibody for selective interaction with neuroblastoma cells. Cultured human neuroblastoma cell lines were used to evaluate the efficiency of siRNA delivery.

Results: The size of liposomes prepared by DAC ranged from 190 to 240 nm; siRNA encapsulation efficiency was up to 50%. An average of 70 and 100 molecules of anti-GD2 antibody per particle were coupled. A significant association of liposomes with neuroblastoma cells as well as effective siRNA delivery was observed only when anti-GD2 antibody was coupled. Preliminary data suggest delivery of siRNA using anti-GD2-liposomes occurs via GD2-mediated endocytosis. Vascular endothelial growth factor A (VEGF-A) was down-regulated using siRNA delivered by anti-GD2-liposomes.

Conclusions: DAC and SPIT allow for the straightforward preparation of liposomes for the targeted delivery of siRNA. Anti-GD2-liposomes thus produced can serve as versatile carriers of siRNA to neuroblastoma cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Cell Line, Tumor
  • Centrifugation / methods
  • Drug Compounding / methods
  • Gangliosides / antagonists & inhibitors*
  • Gangliosides / biosynthesis
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics
  • Gene Transfer Techniques*
  • Humans
  • Neuroblastoma / genetics
  • Neuroblastoma / therapy*
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / genetics
  • Real-Time Polymerase Chain Reaction
  • Sterols / chemistry*

Substances

  • Antibodies, Monoclonal
  • Gangliosides
  • RNA, Small Interfering
  • Sterols
  • ganglioside, GD2